Acadia Pharmaceuticals
Acadia plans a Phase III study for a Prader-Willi syndrome candidate following an FDA meeting
SG Tylor
Source – Acadia Pharmaceuticals ACP-101, also known as intranasal carbetocin, has been chosen by Acadia to move forward into a ...
